Thiazolidinediones in the treatment of patients with Post-Transplant-Hyperglycemia or new-onset diabetes mellitus after renal transplantation (NODAT) - A new therapeutic option?
Säemann
Marcus D
MD
Innere Medizin III, Klinische Abteilung für Nephrologie, Medizinische Universität Wien, Vienna, Austria. marcus.saemann@meduniwien.ac.at
Krebs
Michael
M
D000818:Animals; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy* / Q000401:mortality; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation; D011183:Postoperative Complications / Q000188:drug therapy* / Q000401:mortality; D011379:Prognosis; D015996:Survival Rate; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; C089946:2,4-thiazolidinedione